Related references
Note: Only part of the references are listed.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers
Francois Bertucci et al.
MOLECULAR ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer
Dominique J. P. van Uden et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
C. Van Berckelaer et al.
BREAST CANCER RESEARCH (2019)
Association of dermal lymphatic involvement and survival in inflammatory breast cancer
K. A. Hirko et al.
CANCER RESEARCH (2019)
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer
Jay P. Reddy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer
B Overmoyer et al.
CANCER RESEARCH (2018)
Abstract OT3-04-01: A phase I of olaparib with radiation therapy in patients with inflammatory, loco-regionally advanced or metastatic TNBC (triple negative breast cancer) or patient with operated TNBC with residual disease
YM Kirova et al.
CANCER RESEARCH (2018)
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer
Mousumi Majumder et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study
Reshma Jagsi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
Naoko Matsuda et al.
JAMA ONCOLOGY (2018)
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
Xu Liang et al.
BREAST CANCER RESEARCH (2018)
Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy
Monika Brzezinska et al.
GLAND SURGERY (2018)
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and-2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga et al.
ANNALS OF ONCOLOGY (2017)
Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database
Jieqiong Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer
Michal Mego et al.
ONCOTARGET (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer
Xiaoping Wang et al.
Oncotarget (2017)
A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18
Hongliang Chen et al.
BREAST (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy
Komal Jhaveri et al.
CLINICAL BREAST CANCER (2016)
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors
Christopher A. Hamm et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations
Jeffrey S. Ross et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis
Tamer M. Fouad et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome
Jennifer M. Matro et al.
CLINICAL BREAST CANCER (2015)
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
Francois Bertucci et al.
ONCOTARGET (2015)
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
Natasha M. Rueth et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
Prevalence of Papillomaviruses, Polyomaviruses, and Herpesviruses in Triple-Negative and Inflammatory Breast Tumors from Algeria Compared with Other Types of Breast Cancer Tumors
Marilys Corbex et al.
PLOS ONE (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Risk factors for inflammatory breast cancer
R. L. Atkinson et al.
CANCER RESEARCH (2013)
Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets
Steven J. Van Laere et al.
CLINICAL CANCER RESEARCH (2013)
18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging
David Groheux et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers
Catherine Schairer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Sarah J. Conley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
MRI findings of inflammatory breast cancer, locally advanced breast cancer, and acute mastitis: T2-weighted images can increase the specificity of inflammatory breast cancer
Takayoshi Uematsu
BREAST CANCER (2012)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inflammatory breast carcinoma and locally advanced breast carcinoma: characterisation with MR imaging
V. Girardi et al.
RADIOLOGIA MEDICA (2011)
Human Mammary Tumor Virus in Inflammatory Breast Cancer
Beatriz G. -T. Pogo et al.
CANCER (2010)
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Imaging in the Staging and Prognosis of Inflammatory Breast Cancer
Jean-Louis Alberini et al.
CANCER (2009)
Retrospective Studyof 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data
Selin Carkaci et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility
Silvia Giampieri et al.
NATURE CELL BIOLOGY (2009)
Molecular targets for treatment of inflammatory breast cancer
Hideko Yamauchi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells
Mei-Ren Pan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The epidemiology of inflammatory breast cancer
Paul H. Levine et al.
SEMINARS IN ONCOLOGY (2008)
Pathologic aspects of inflammatory breast carcinoma: Part I. Histomorphology and differential diagnosis
Erika Resetkova
SEMINARS IN ONCOLOGY (2008)
The role of locoregional therapy in inflammatory breast cancer
Wendy A. Woodward et al.
SEMINARS IN ONCOLOGY (2008)
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings
Wei T. Yang et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Inflammatory breast cancer (IBC) and patterns of recurrence - Understanding the biology of a unique disease
Massimo Cristofanilli et al.
CANCER (2007)
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer
N. Cabioglu et al.
ANNALS OF ONCOLOGY (2007)
Benign Breast Lesions that Simulate Malignancy: Magnetic Resonance Imaging with Radiologic-Pathologic Correlation
Alfonso Iglesias et al.
CURRENT PROBLEMS IN DIAGNOSTIC RADIOLOGY (2007)
Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
KW Hance et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
High incidence of HER-2 positivity in inflammatory breast cancer
M Parton et al.
BREAST (2004)
Human murine mammary tumour virus-like agents are genetically distinct from endogenous retroviruses and are not detectable in breast cancer cell lines or biopsies
C Mant et al.
VIROLOGY (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Insulin-like growth factors and neoplasia
MN Pollak et al.
NATURE REVIEWS CANCER (2004)
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
TJ Key et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: Distinct clinicopathologic entities?
WF Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Inflammatory breast carcinoma:: Mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases
I Günhan-Bilgen et al.
RADIOLOGY (2002)
Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas
F Fina et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
